16,284 resources
Start Prev Rows 7800 - 8000 Next
| Package | Version | Identity | Name/Title | Status | FMM | WG | Date |
|---|---|---|---|---|---|---|---|
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.2468 | CRE (Combination Tests that include Enterobacterales by Culture and Identification) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.2469 | Tests for Carbapenem Susceptibility [Meropenem and Doripenem] | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.2470 | Enterobacterales species [excluding Proteus spp., Providencia spp., and Morganella spp.] (Organism or Substance in Lab Results) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.2471 | Proteus spp., Providencia spp., and Morganella spp. (Organism or Substance in Lab Results) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.2473 | Enterobacterales species [Carbapenem Resistant] (Organism or Substance in Lab Results) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.2474 | Enterobacterales species [Carbapenemase Producing] (Organism or Substance in Lab Results) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.2475 | Aortic valve stenosis (Disorders) (SNOMED) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.2476 | Aortic valve stenosis (Disorders) (ICD10CM) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.2477 | Anotia (Disorders) (ICD10CM) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.2478 | Microtia (Disorders) (ICD10CM) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.2479 | Microtia (Disorders) (SNOMED) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.2480 | Anotia (Disorders) (SNOMED) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.2482 | Anophthalmia (Disorders) (SNOMED) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.2483 | Anophthalmia (Disorders) (ICD10CM) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.2484 | Microphthalmia (Disorders) (SNOMED) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.2485 | Microphthalmia (Disorders) (ICD10CM) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.2486 | Atrial septal defect (Disorders) (SNOMED) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.2487 | Atrial septal defect (Disorders) (ICD10CM) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.2488 | Fetal Aortic valve stenosis (Disorders) (SNOMED) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.2489 | Congenital Posterior Urethral Valves (Disorders) (SNOMED) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.2490 | Congenital Posterior Urethral Valves (Disorders) (ICD10CM) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.2491 | Bladder Exstrophy (Disorders) (SNOMED) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.2492 | Bladder Exstrophy (Disorders) (ICD10CM) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.2493 | Encephalocele (Disorders) (SNOMED) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.2494 | Fetal Encephalocele (Disorders) (ICD10CM) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.2495 | Encephalocele (Disorders) (ICD10CM) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.2496 | Choanal Atresia (Disorders) (SNOMED) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.2497 | Choanal Atresia (Disorders) (ICD10CM) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.2498 | Cloacal Exstrophy (Disorders) (SNOMED) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.2499 | Cloacal Exstrophy (Disorders) (ICD10CM) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.2500 | Renal Agenesis or Hypoplasia (Disorders) (SNOMED) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.2501 | Renal Agenesis or Hypoplasia (Disorders) (ICD10CM) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.2502 | Trisomy 13 (Disorders) (SNOMED) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.2503 | Trisomy 13 (Disorders) (ICD10CM) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.2504 | Fetal Trisomy 13 (Disorders) (SNOMED) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.2505 | Trisomy 13 (Tests for Trisomy 13 Chromosomal Anomaly) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.2506 | Galactosemia (Disorders) (SNOMED) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.2507 | Galactosemia (Disorders) (ICD10CM) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.2508 | Galactosemia (Tests for Galactose_1_Phosphate Uridyltransferase [Quantitative] in Blood) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.2509 | Galactosemia (Tests for Galactokinase (GALK) [Quantitative] in Blood) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.2510 | Galactosemia (Tests for UDP_galactose 4' epimerase (GALE) [Quantitative] in Blood) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.2511 | Galactosemia (Tests for Galactose_1_Phosphate Uridyltransferase [Quantitative]) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.2512 | Galactosemia (Tests for Galactokinase (GALK) [Quantitative]) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.2513 | Galactosemia (Tests for UDP_galactose 4' epimerase (GALE) [Quantitative]) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.2514 | Galactosemia (Tests for GALT gene allele 1) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.2515 | Galactosemia (Tests for GALT gene allele 2) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.2516 | Hypospadias (Disorders) (SNOMED) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.2517 | Hypospadias (Disorders) (ICD10CM) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.2518 | Trisomy 18 (Disorders) (SNOMED) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.2519 | Fetal Trisomy 18 (Disorders) (SNOMED) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.2520 | Fetal Trisomy 18 (Disorders) (ICD10CM) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.2521 | Trisomy 18 (Disorders) (ICD10CM) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.2522 | Trisomy 18 (Tests for Trisomy 18 Chromosomal Anomaly) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.2523 | Chlamydia trachomatis Infection (Tests for unspecified Chlamydia species by Culture and Identification Method) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.2524 | Chlamydia trachomatis Infection (Tests for unspecified Chlamydia species Nucleic Acid) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.2525 | Chlamydia trachomatis Infection (Tests for unspecified Chlamydia species Antigen) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.2526 | Chlamydia trachomatis Infection (Combination Tests that include Chlamydia trachomatis Nucleic Acid) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.2527 | Chlamydia species [Unspecified] (Organism or Substance in Lab Results) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.2528 | Ventricular septal defect (Disorders) (SNOMED) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.2529 | Ventricular septal defect (Disorders) (ICD10CM) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.2530 | Gonorrhea (Combination Tests that include Neisseria Gonorrhea Nucleic Acid) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.2531 | Intracellular Gram Negative Diplococcus (Organism or Substance in Lab Results) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.2532 | Congenital Cytomegalovirus (Tests for CMV Nucleic Acid) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.2533 | Congenital Cytomegalovirus (Tests for CMV Antibody) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.268 | Mumps (Tests for mumps virus IgM Antibody) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.272 | Present or Positive Lab Result Value | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.282 | Varicella (Tests for Varicella zoster virus by Culture and Identification Method) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.283 | Varicella (Tests for Varicella zoster virus Nucleic Acid) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.285 | Encephalitis (Disorders) (ICD10CM) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.287 | Varicella (Organism or Substance in Lab Results) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.289 | Carbon Monoxide Poisoning (Disorders) (ICD10CM) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.293 | Toxic Effects of Lead (Disorders) (ICD10CM) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.297 | Measles (Tests for measles virus Nucleic Acid) | active | 2025-03 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.299 | Measles (Tests for measles virus IgM Antibody) | active | 2025-03 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.300 | Meningococcal Disease (Organism or Substance in Lab Results) | active | 2023-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.301 | Shigellosis (Tests for Shigella species by Culture and Identification Method) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.307 | Leptospirosis (Tests for Leptospira IgM Antibody) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.308 | Invasive Pneumococcal Disease (Tests for Streptococcus pneumoniae Nucleic Acid) | active | 2023-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.310 | Bacteria (Tests by Culture and Identification Method) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.311 | Viruses (Tests by Culture and Identification Method) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.316 | Rubella (Tests for rubella virus IgM Antibody) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.317 | Shigellosis (Tests for Shigella species Nucleic Acid) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.319 | Fungi (Tests by Culture and Identification Method) | active | 2024-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.322 | Pesticide Related Illness (Disorders) (ICD10CM) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.329 | Apnea (SNOMED) | active | 2024-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.330 | Apnea (ICD10CM) | active | 2024-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.333 | Shigellosis (Organism or Substance in Lab Results) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.335 | Influenza (Tests for influenza A virus by Culture and Identification Method) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.336 | Influenza (Tests for influenza A or B virus Nucleic Acid) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.340 | Influenza (influenza A or B virus in Lab Results) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.341 | Campylobacteriosis (Organism or Substance in Lab Results) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.342 | Campylobacteriosis (Tests for Campylobacter species by Culture and Identification Method) | active | 2023-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.343 | Campylobacteriosis (Tests for Campylobacter species Nucleic Acid) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.344 | Campylobacteriosis (Tests for Campylobacter species Antigen) | active | 2023-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.349 | Hepatitis A (Tests for hepatitis A virus IgM Antibody) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.353 | Diarrhea (SNOMED) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.356 | HIV Infection (Organism or Substance in Lab Results) | active | 2023-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.359 | Botulism (Disorders) (SNOMED) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.362 | Hansen’s Disease (Disorders) (SNOMED) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.365 | Silicosis (Disorders) (SNOMED) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.366 | Silicosis (Disorders) (ICD10CM) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.371 | Cryptosporidiosis (Organism or Substance in Lab Results) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.372 | Cryptosporidiosis (Tests for Cryptosporidium species Nucleic Acid) | active | 2023-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.375 | Cyclosporiasis (Organism or Substance in Lab Results) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.376 | Cyclosporiasis (Tests for Cyclospora cayetanensis Nucleic Acid) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.379 | Giardiasis (Tests for Giardia species Nucleic Acid) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.384 | Listeriosis (Tests for Listeria monocytogenes Nucleic Acid) | active | 2024-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.386 | Vibriosis (Organism or Substance in Lab Results) | active | 2024-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.388 | Vibriosis (Tests for Vibrionaceae species [except Toxigenic Vibrio cholera O1 and O139] Nucleic Acid) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.390 | Trichinellosis (Tests for Trichinella species Antibody) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.395 | Syphilis (Disorders) (SNOMED) | active | 2024-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.396 | Syphilis (Disorders) (ICD10CM) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.398 | Hepatitis C Virus Infection (Tests for hepatitis C virus Nucleic Acid) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.399 | Hepatitis C Virus Infection (Tests for hepatitis C virus Antigen) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.40 | STEC Infection (Disorders) (SNOMED) | active | 2023-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.400 | Hepatitis B Virus Infection (Tests for hepatitis B virus IgM Antibody) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.401 | Hepatitis B Virus Infection (Tests for hepatitis B virus surface Antigen) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.403 | Hepatitis B Virus Infection (Tests for hepatitis B virus Nucleic Acid) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.405 | Hantavirus Infection and Diseases (Disorders) (ICD10CM) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.407 | Hepatitis C Virus Infection (Tests for hepatitis C virus Antibody) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.408 | Hepatitis B Virus Infection (Organism or Substance in Lab Results) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.422 | Tuberculosis (Disorders) (SNOMED) | active | 2023-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.427 | STEC Infection (Tests for Shiga toxin genes, or STEC, EHEC, or E. coli O157 Nucleic Acid) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.43 | Gonorrhea [Cervicitis Urethritis] (Disorders) (SNOMED) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.436 | Coccidioidomycosis (Tests for Coccidioides species IgM Antibody) | active | 2024-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.437 | Coccidioidomycosis (Tests for Coccidioides species Nucleic Acid) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.438 | Coccidioidomycosis (Tests for Coccidioides species Antigen) | active | 2024-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.44 | Gonorrhea [Cervicitis Urethritis] (Disorders) (ICD10CM) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.445 | Legionellosis (Tests for Legionella species Antigen) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.446 | Legionellosis (Tests for Legionella species Nucleic Acid) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.451 | Tuberculosis (Disorders) (ICD10CM) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.460 | HIV Infection or AIDS (Disorders) (SNOMED) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.464 | Malaria (Tests for Plasmodium species Nucleic Acid) | active | 2023-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.468 | Leptospirosis (Tests for Leptospira Nucleic Acid) | active | 2024-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.471 | Leptospirosis (Tests for Leptospira Antibody [Quantitative] by Agglutination) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.472 | Leptospirosis (Tests for Leptospira Antibody) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.476 | Babesia species (Tests by Microscopic Observation in Blood) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.478 | Anthrax (Tests for Bacillus anthracis by Culture and Identification Method) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.479 | Anthrax (Tests for Bacillus anthracis Nucleic Acid) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.48 | Salmonellosis (Disorders) (SNOMED) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.480 | Anthrax (Tests for Bacillus anthracis Antigen) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.481 | Anthrax (Tests for Bacillus anthracis Antibody) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.494 | Ehrlichiosis (Organism or Substance in Lab Results) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.496 | Q Fever (Tests for Coxiella burnetii IgM IgG Antibody [Excluding Quantitative IFA Tests for IgG Antibody against Phase I or II Antigen]) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.500 | Q Fever (Tests for Coxiella burnetii Nucleic Acid) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.505 | Toxic Shock Syndrome (TSS) (Disorders) (SNOMED) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.507 | Toxic Shock Syndrome (TSS) (Disorders) (ICD10CM) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.512 | Brucellosis (Tests for Brucella species Nucleic Acid) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.515 | Brucellosis (Tests for Brucella species Antibody [Quantitative]) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.516 | Brucellosis (Organism or Substance in Lab Results) | active | 2024-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.519 | Dengue Virus Infection (Tests for dengue virus Nucleic Acid) | active | 2024-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.523 | Dengue Virus Infection (Tests for dengue virus Antigen) | active | 2024-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.524 | Dengue Virus Infection (Tests for dengue virus IgG or Total Antibody [Quantitative]) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.525 | Dengue Virus Infection (Tests for dengue virus IgM Antibody) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.527 | Dengue Virus Infection (Tests for dengue virus IgG or Total Antibody [Qualitative]) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.530 | Borrelia species (Tests for Nucleic Acid) | active | 2024-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.531 | Lyme Disease (Tests for Borrelia burgdorferi IgM IgG Antibody by Immunoblot) | active | 2024-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.532 | Lyme Disease (Tests for Borrelia burgdorferi Antibody by Immunoassay) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.534 | Smallpox (Organism or Substance in Lab Results) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.548 | St. Louis Encephalitis Virus Infection (Tests for Saint Louis encephalitis virus Antibody [Qualitative]) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.550 | Syphilis (Tests for Treponema pallidum Nucleic Acid) | active | 2024-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.553 | Anaplasma species (Tests by Microscopic Observation) | active | 2023-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.555 | Yellow Fever (Tests for yellow fever virus Nucleic Acid) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.557 | Yellow Fever (Tests for yellow fever virus Antibody [Quantitative]) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.56 | Diarrhea (ICD10CM) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.560 | West Nile Virus Infection (Tests for West Nile virus Nucleic Acid) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.569 | Plague (Tests for Yersinia pestis Nucleic Acid) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.58 | Pertussis (Tests for Bordetella pertussis Nucleic Acid) | active | 2023-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.595 | Tularemia (Tests for Francisella tularensis Nucleic Acid) | active | 2023-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.598 | Tularemia (Tests for Francisella tularensis Antibody) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.6 | Diphtheria (Disorders) (SNOMED) | active | 2023-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.605 | Organisms (Tests by Microscopic Observation by Acid Fast Stain) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.606 | Tuberculosis (Organism or Substance in Lab Results) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.614 | Pertussis (Tests for Bordetella pertussis Toxin Antibody) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.621 | Inspiratory Whoop (ICD10CM) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.632 | Chlamydia trachomatis Infection [Secondary Sites Complications] (Disorders) (SNOMED) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.645 | Pertussis (Test Panels for Bordetella pertussis and Bordetella parapertussis Nucleic Acid) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.648 | Vomiting (ICD10CM) | active | 2023-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.650 | Jaundice (SNOMED) | active | 2023-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.652 | Bacteria (Tests in Specimen from Normally Sterile Site by Culture and Identification Method) | active | 2024-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.660 | Hypertonia [Excluding Congenital Hypertonia] (SNOMED) | active | 2024-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.662 | Chest Pain (ICD10CM) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.663 | Erythema Nodosum (SNOMED) | active | 2024-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.664 | Congenital Zika Syndromes (SNOMED) | active | 2024-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.665 | Congenital Zika Syndromes (ICD10CM) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.666 | Guillain Barré syndrome (Disorders) (SNOMED) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.668 | Rash (SNOMED) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.671 | Fever (ICD10CM) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.672 | Arthralgia (SNOMED) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.673 | Arthralgia (ICD10CM) | active | 2023-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.674 | Conjunctivitis (SNOMED) | active | 2024-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.675 | Conjunctivitis (ICD10CM) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.676 | Pregnant (SNOMED) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.677 | Postpartum (SNOMED) | active | 2024-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.678 | Postpartum (ICD10CM) | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.679 | Hearing Loss (SNOMED) | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.680 | Abdominal Pain (ICD10CM) | active | 2023-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.681 | Abdominal Pain (SNOMED) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.686 | Erythema Multiforme (SNOMED) | active | 2023-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1146.687 | Myalgia (ICD10CM) | active | 2023-01 |
FHIR